BidaskClub upgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a hold rating in a research report released on Saturday, BidAskClub reports.

Several other equities analysts also recently issued reports on PRTK. SVB Leerink cut their price objective on shares of Paratek Pharmaceuticals from $15.00 to $14.00 and set an outperform rating on the stock in a report on Tuesday, August 11th. ValuEngine raised shares of Paratek Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, August 11th. HC Wainwright lifted their price objective on shares of Paratek Pharmaceuticals from $18.00 to $19.00 and gave the stock a buy rating in a research note on Tuesday, August 11th. Finally, Zacks Investment Research downgraded Paratek Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $15.71.

Shares of PRTK opened at $5.83 on Friday. The company has a 50 day moving average of $4.63 and a two-hundred day moving average of $4.43. Paratek Pharmaceuticals has a twelve month low of $2.50 and a twelve month high of $6.41. The company has a market cap of $264.61 million, a price-to-earnings ratio of -1.94 and a beta of 1.53.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings data on Monday, August 10th. The specialty pharmaceutical company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.39). The firm had revenue of $9.33 million during the quarter, compared to analysts’ expectations of $34.34 million. As a group, research analysts anticipate that Paratek Pharmaceuticals will post -1.78 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA raised its position in Paratek Pharmaceuticals by 121.2% during the first quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,570 shares in the last quarter. Citigroup Inc. grew its stake in shares of Paratek Pharmaceuticals by 32.2% during the 1st quarter. Citigroup Inc. now owns 14,227 shares of the specialty pharmaceutical company’s stock worth $45,000 after purchasing an additional 3,469 shares during the period. HighTower Advisors LLC acquired a new stake in shares of Paratek Pharmaceuticals during the 1st quarter worth approximately $49,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Paratek Pharmaceuticals during the 2nd quarter valued at approximately $56,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Paratek Pharmaceuticals in the 1st quarter valued at $61,000. Hedge funds and other institutional investors own 46.77% of the company’s stock.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

Recommended Story: Learning About the VIX – Volatility Index

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.